Compare HCWB & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCWB | BBLG |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.4M |
| IPO Year | 2021 | N/A |
| Metric | HCWB | BBLG |
|---|---|---|
| Price | $0.31 | $1.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 708.3K | 5.9K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,099,750.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.70 |
| 52 Week High | $17.80 | $5.98 |
| Indicator | HCWB | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 46.99 |
| Support Level | $0.25 | $1.08 |
| Resistance Level | $0.51 | $1.36 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 2.00 | 9.18 |
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.